# Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

> **NCT04641728** · PHASE2 · UNKNOWN · sponsor: **Saitama Medical University International Medical Center** · enrollment: 28 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT04641728
- **Lead sponsor:** Saitama Medical University International Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-08-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04641728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04641728, "Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04641728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*